Richard Zorowitz, MD
Physical Medicine & Rehabilitation · Washington, DCNPI 1568493237
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $37,287 of the $57,058 with a category attached, or 65.3%. 12 manufacturers reported payments, led by Ipsen Innovation at 33.3% of the total. Reporting peaked in 2024 at $23,607 and has fallen 60.8% since, to $9,251 in 2025. Among physical medicine & rehabilitation clinicians in DC with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 55 payments — averaging $1037.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Ipsen Innovation$19K
- Ipsen Pharma SAS$17K
- SPR Therapeutics, Inc$7K
- Ipsen Biopharmaceuticals, Inc$6K
- Ipsen Biopharm Limited$4K
- AbbVie$3K
- plus $731 from 6 others
Across 200 payments — averaging $2499.38 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Ipsen Pharma SAS$419K
- AbbVie$31K
- Sunovion Pharmaceuticals Inc.$29K
- Ipsen Innovation$21K
What the payments were for
- Consulting fees$37,28765%
- Speaking & faculty fees$1,4202%
- Travel & lodging$16,55629%
- Food & beverage$1,7963%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Ipsen Innovation | 4 | $18,995 |
| Ipsen Pharma SAS | 8 | $17,025 |
| SPR Therapeutics, Inc | 21 | $6,681 |
| Ipsen Biopharmaceuticals, Inc | 11 | $6,038 |
| Ipsen Biopharm Limited | 1 | $4,260 |
| AbbVie | 2 | $3,328 |
| Merz Pharmaceuticals, LLC | 3 | $258 |
| Microtransponder, Inc. | 1 | $190 |
| Merz North America, Inc. | 1 | $124 |
| Revance Therapeutics, Inc. | 1 | $122 |
| AstraZeneca | 1 | $20 |
| Smith+Nephew | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- DYSPORT$32,876
- SPRINT PNS System$5,892
- DAXXIFY$122
How this compares
$57,058 in reported general payments places this provider in the 95th percentile of 41 physical medicine & rehabilitation providers in District of Columbia.
See all physical medicine & rehabilitation providers in District of Columbia →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| DysportAbobotulinumtoxina | 13 | $24,576 |
| BotoxOnabotulinumtoxina | 14 | $20,828 |
| Dantrolene Sodium | 25 | $4,370 |
| Gabapentin | 98 | $2,872 |
| Baclofen | 66 | $2,473 |
| AmantadineAmantadine Hcl | 22 | $2,452 |
| Levetiracetam | 13 | $1,815 |
| Duloxetine Hcl | 35 | $1,222 |
| Midodrine Hcl | 15 | $907 |
| Pregabalin | 30 | $776 |
| Fentanyl | 12 | $725 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 30 | $658 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 28 | $608 |
| Methadone Hcl | 12 | $595 |
| Methylphenidate ErMethylphenidate Hcl | 22 | $546 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Ipsen Biopharmaceuticals, IncDysport | $6,038 | $24,57613 claims |
| AbbVieBotox | $3,328 | $20,82814 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 41 physical medicine & rehabilitation providers in District of Columbia.
Other physical medicine & rehabilitation in Washington
- Ryan AschenbrenerWashington$8K
- Suzanne GroahWashington$2K
- Eric WisotzkyWashington$2K
- Nikolai KhromouchkineWashington$2K
- Erika GosaiWashington$1K
- Nathan YokelWashington$1K
- Howard GilmerWashington$700
- Jasmine MalhotraWashington$670
- Michael WrotenWashington$586
- Megha MandalaywalaWashington$464
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.